Can drug design inhibit abuse?

Journal of Psychoactive Drugs

Volumn 37, Issue 4, 2005, Pages 343-362

  Coleman, John J ^a   Bensinger, Peter B ^b   Gold, Mark S ^c   Smith, David E ^d   Bianchi, Robert P ^a   DuPont, Robert L ^e  

^a Prescription Drug Research Center   (United States)

^b Bensinger DuPont and Associates   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Haight Ash bury Free Clinics   (United States)

^e Institute for Behavior and Health   (United States)

Author keywords

Abuse resistance; Abuse resistant technology; Controlled substances; Drug abuse; Prescription drugs

Indexed keywords

ACETYLSALICYLIC ACID; AMPHETAMINE DERIVATIVE; ANABOLIC AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; COCAINE; DEXTROPROPOXYPHENE; DRONABINOL; FENTANYL; FENTANYL CITRATE; HYDROCODONE; METHADONE; METHAMPHETAMINE; METHYLIN ER; METHYLPHENIDATE; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; OPIATE; OXYCODONE; PARACETAMOL; PENTAZOCINE; PERCOCET; STEROID; TESTOSTERONE; TETRAHYDROCANNABINOL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ATTENTION DEFICIT DISORDER; CANCER PAIN; CHRONIC PAIN; DRUG ABUSE; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOGONADISM; OPIATE ADDICTION; RESPIRATION DEPRESSION; SIDE EFFECT; UNITED STATES; VOMITING;

EID: 31444436940     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2005.10399808     Document Type: Article

References (100)

1. Acker, C.J. 2003. Regulating psychoactive drugs. In: M.L. Meldrum(Ed.) Opioids and Pain Relief: A Historical Perspective. Vol 25. Seattle: IASP Press.
2. Acker, C.J. 2002. Creating the American Junkie: Addiction Research in the Classic Era of Narcotic Control. Baltimore, MD: Johns Hopkins University Press.
3. Alza Corporation. 2003a. Information for patients taking Concerta or their parents or caregivers (PI). In: McNeil Consumer & Specialty Pharmaceuticals (Ed.) Prescribing Information. Ft. Washington, PA: MCSP
4. Alza Corporation. 2001. Concerta™—A success story: Optimizing drug delivery: The Concerta Experience. Delivery Times I (1): 1-12 (Available at: www.alza.cornlpdf/vol_l_l.pdf)
5. Alza Corporation. 2000. Final Draft Labeling for Concerta Extended-Release Tablets/Attachment to Approval Letter: Concerta CII/NDA 21-121. Available at: www.fda.gov/cder/foi/label/2000/21121 Ibl.pdf.
6. American Academy of Child and Adolescent Psychiatry (AACAP). 2002. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry 41 (2Supplement/Feb): 26S-49S.
7. Anabolic Steroid Control Act. 2004. 21 USC 802, as amended.
8. Anderson, D.T. & Muto, J.J. 2000a. Duragesic transdermal patch: Postmortem tissue distribution of fentanyl in 25 cases. Journal of Analytical Toxicology 24 (7): 627-34.
9. Anderson, D.T. & Muto, J.J. 2000b. Case studies involving fentanyl part I: Duragesic patch—25 fatalities; Part II: Sublimaze injection—15 fatalities. Paper presented at the American Academy of Forensic Sciences, Reno, NV.
10. Baum, C.; Hsu, J.P. & Nelson, R.C. 1987. The impact of the addition of naloxone on the useand abuse ofpentazocine. Public Health Reports 102 (4): 426-29.
11. Bradley, C. 1937. The behavior of children receiving Benzedrine. American Journal of Psychiatry 94: 577-85.
12. Breithaupt, M. 2001. Report of two Duragesic-related deaths. Personal communication (Letter to John J. Coleman from Rockland County, NY. Office of the Chief Medical Examiner).
13. Brookoff, D. 1993. Abuse potential of various opioid medications. Journal of General Internal Medicine 8 (12): 688-90.
14. Brookoff, D.; Campbell, E.A. & Shaw, L.M. 1993. The underreporting of cocaine-related trauma: Drug Abuse Warning Network reports vs hospital toxicology tests. American Journal of Public Health 83(3): 369-71.
15. Brown, S.D. Jr & Landry, F.J. 2001. Recognizing, reporting, and reducing adverse drug reactions. Southern Medical Journal 94 (4): 370-73.
16. Campbell, PS. & Eckenhoff, J B., inventors;Alza Corporation, PaloAlto, CA, assignee.1984/1987 Patent Application: Transdermal therapeutic system having improved delivery characteristics. US patent 4704282. June 29.
17. Code of Federal Regulations. 1970. 21 CFR I 308. 12(c)(l), 21CFRI 308 13(e)(7), 21CFR1 308.1 5(c)(5), 21CFRI 308.43; 21USC8O1.
18. Challoner, K.R.; McCaron, M.M. & Newton, E.J. 1990. Pentazocine (Talwin) intoxication: Report of 57 cases. Journal of Emergency Medicine 8 (1): 67-74.
19. Coleman N. 2004 M. Buyer beware: The danger of purchasing pharmaceuticals over the Internet. Statement of US Senator Norm Colemn on July 22 to Senate Committee on Governmental Affairs Available at: hsgac.senate.gov/index.cftnlaon=Hearing;TMy&TMyID=J6fflmglD=I83
20. Controlled Substances Act. 1970a. 21USC801. et. seq. Vol Sect. 301 (PL-513)
21. Controlled Substances Act, as amended. 1970b. 21 USC 801, et seq. (21 CFR 1300 01).
22. Controlled Substances Act. 1970c. Title 21. Vol 21 USC 8 l l(f).
23. Controlled Substances Act. 1970d. 21USC812(a).
24. Controlled Substances Act of 1970. 1970e. 21 USC 801(I).
25. Cullen, D.J.; Bates, D.W.; Small, S.D.; Cooper, J.B.; Nemeska, A.R & Leape, L.L. 1995. The incident reporting system does not detect adverse drug events: A problem for quality improvement. Joint Commission Journal on Quality Improvement 21 (10): 541-48.
26. DeSio J.; Bacon, D.R.; Peer, G. & Lema, M.J. 1993. Intravenous abuse of transdermal fentanyl therapy in a chronic pain patient. Anesthesiology 79: 1139-41.
27. Fattore L.; Cossu, G.; Spano, M.S.; Deiana, S.; Fadda, P.; Scherma, M. & Fratta, W. 2004. Cannabinoids and reward: Interactions with the opioid system. Critical Reviews in Neurobiology 16 (1-2): 147-58.
28. Fishbain DA. 1999. The association of chronic pain and suicide. Seminars in Clinical Neuropsychiatry 4 (3): 221-27.
29. Fishbain, D.A.; Goldberg, M.; Rosomoff R.S. & Rosomoff, H. 1991. Completed suicide i n chronic pain. Clinical Journal of Pain 7 (1): 29-36.
30. Florida Department of Law Enforcement. 2004. 2003 Report by Florida Medical Examiners Commission on Drugs Identified in Deceased Persons. Available at: www.fdle.state.fl.us/press_releases/20040526_MER_Report.html.
31. Gandhi, T.K.; Seger, D.L. & Bates, D.W. 2000. Identifying drug safety issues: From research to practice. International Journal ofQualitv Health Care 12 (I): 69-76.
32. Glajchen, M. 2001. Chronic pain: Treatment barriers and strategies for clinical practice. Journal of the American Board of Family Practitioners 14(3): 211-18.
33. Hohenstein, K. 2001. Just what the doctor ordered: The Harrison antinarcotic act, the Supreme Court, and the federal regulation of medical practice, 1915-1919. Journal of Supreme Court History 26 (3): 231-56.
34. Institute for Behavior and Health Inc (IBH). 2004. Existing law enforcement and drug supply data sources related to the nonmedical use of prescription stimulants-update. Paper presented at the Third Meeting of the Advisory Committee on Non-Medical Use of Prescription Stimulants, Washington. DC. Nov. 16.
35. Jaffe, S.L. 2002. Failed attempts at intranasal abuse of Concerta. [Comment] Journal of the American Academy of Child and Adolescent Psychiatry 41 (1): 5.
36. Jamison, R.N.; Kauffman, J. & Katz, N.P. 2000. Characteristics of methadone maintenance patients with chronic pain. Journal of Pain Symptom Managementl9: 53-62.
37. Janssen Pharmaceutica LP. 2003. Package Insert, Duragesic C-11 [fentanyl transdermal system]. Titusville, NJ: Janssen Pharmaceutica LP.
38. Jost, U.; Wolter E. & Bohrer, H. 2004. Repeated improper intravenous injection of fentanyl from a transdermal system. Deutsche Medizinische Wochenschrift 129 (7): 313-14.
39. Kopstein, A. 1992. Drug abuse related emergency room episodes in the United States. British Journal of the Addictions 87 (7): 1071-75.
40. Kuhlman, J.J., Jr.; McCaulley, R.; Valouch, T.J. & Behonick, G.S. 2003. Fentanyl use, misuse, and abuse: A summary of 23 postmortem cases. Journal of Analytical Toxicology 27 (7): 499-504.
41. Lahmeyer H.W. & Steingold, R G. 1980. Pentazocine and tripelennamine: A drug abuse epidemic? International Journal of the Addictions I 5 (8): 1219-32.
42. Lesesne, C.A.; Visser, S.N. & White, C. 2003. Attention-deficit/hyperactivity disorder in school-aged children: Association with maternal mental health and use of health care resources. Pediatrics 111(5): SI232(1236).
43. Liappas, I.A.; Dimopoulos, N.P.; Mellos, E.; Gitsa, O.E.; Liappas, A.l. & Rabavilas, A.D. 2004. Oral transmucosal abuse oftransdermal fentanyl. Journal of Psychopharmacology 18 (2): 277-80.
44. Liu, J. & Schulteis, G. 2004. Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence. Pharmacology, Biochemistry and Behavior 79 (1): 101-08.
45. Lucas J., & Ryan, J. 2004. Lawmen smash unlikely drug alliance. Newark-Star Ledger Nov. 12: 21.
46. Mathias, R. 1997. Rate and duration of drug activity play major roles in drug abuse, addiction, and treatment. NIDA Notes 12 (2): 8-11.
47. Meadows, M. 2003. Prescription drug abuse: FDA and SAMHSA join forces. FDA Consumer Magazine (U.S. Food and Drug Administration) 37 (2, March-April).
48. Meier, B. 2003. Pain Killer: A "Wonder" Drug's Trail of Addiction and Death. New York: Rodale.
49. National Center on Addiction and Substance Abuse (CASA) & Beau Dietl & Associates (BDA). 2004. You’ve Got Drugs! Prescription Drug Pushers on the Internet. Available at: www.casacolumbia.org/absolutenrnltemplates/PressReleases.asp?articleid=356&zoneid=6I
50. National Institute on Drug Abuse (NIDA). 2000. Research Report Series: Anabolic Steroid Abuse. Washington, DC.: US Department of Health & Human Services.
51. National Narcotics Intelligence Consumers Committee. 1980. The Supply of Drugs to the U.S. Illicit Market From Foreign and Domestic Sources in 1980 (With Projections Through 1984). Rockville, MD: USGPO.
52. NDCHealth Inc. 2004. NDCHealth Top200Drugsfor 2003 by U.S. Sales. Atlanta, GA: NDCHealth.
53. New River Pharmaceuticals. 2004. Technology: Conditionally Bioreversible Derivatives. Available at: www.nrpharma.com/company/index.htm.
54. New York Times Editorial Staff. 2004. Looking for adverse events. New York Times Nov. 27 (Final, Section A): 14.
55. Office of National Drug Control Policy & Department of Justice (ONDCP). 2004a. National Synthetic Drugs Action Plan. Washington, D.C.: US Government Printing Office.
56. Office of National Drug Control Policy (ONDCP). 2004b. National Drug Control Strategy. Washington D.C.: US Government Printing Office.
57. Passik, S.D. & Kirsh, K.L. 2004. Opioid therapy in patients with a history of substance abuse. CNS Drugs 18 (1): 13-25.
58. Poklis, A. 1984. Decline in abuse of pentazocine/tripelennamine (T's and Blues) associated with the addition of naloxone to pentazocine tablets. Drug and Alcohol Dependence 14 (2): 135-40.
59. Prescription Drug User Fee Act. 2002. 21 U.S.C. 301.
60. Rice, K.C. 2003. Analgesic research at the National Institutes of Health: State of the art 1930s to the present. In: M.L. Meldrum (Ed.) Opioids and Pain Relief: A Historical Perspective; Progress in Pain Research and Management. Seattle: IASP Press.
61. Roberts C. D. 1996. Data quality of the Drug Abuse Warning Network. American Journal of Drug and Alcohol Abuse 22 (3): 389-401.
62. Rosenblum, A; Joseph, H; Fong, C.; Kipnis, S.;Cleland, C. & Portenoy, RK. 2003. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. Journal of the American Medical Association 289: 2370-78.
63. Smith, A. 2005. Illegal Drugs? Just click away. Internet is open bazaar for illegal pharms, but shady sites pose little threat to legit drug biz. CNN/Money June 17. (Available at: money.cnn.com/2005/06/17/technology/onlinedrugs/index.htm)
64. Spake, A. 2004. Fake drugs, real worries. U.S. News and World Report Sept. 20: 46-50.
65. Sporer, K.A. 2004. Buprenorphine: A primer for emergency physicians. Annals of Emergency Medicine 43 (5): 580-84.
66. Substance Abuse and Mental Health Services Administration (SAMHSA). 2003. Opioid drugs in maintenance and detoxification treatment of opiate addiction; Addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications; interim final rule. Federal Register 68 (99): 27937-39.
67. Swisher J.D. & Hu, T.W. 1984. A review ofthe reliability and validity of the Drug Abuse Warning Network. International Journal of the Addictions 19 (1): 57-77.
68. Ungerleider, J.T.; Lundberg, G.D.; Sunshine, I. & Walberg, C.B. 1980. The Drug Abuse Warning Network (DAWN) Program. Toxicologic verification of I,008 emergency room “mentions.” Archives of General Psychiatry 37 (I): 106-09.
69. Unimed Pharmaceuticals Inc. 1996. Supplemental Petition to Reschedule Dronabinol. Part B. Filed with Drug Enforcement Administration; Arlington VA. Unpublished.
70. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (USDHHS). 2005. Treatment Episode Data Set (TEDS). Rockville, MD: USGPO.
71. US Department of Health and Human Services (USDHHS). 2004. Monitoring the Future 2003 Survey. Rockville, MD: USGPO.
72. US Department of Health and Human Services (USDHHS). Substance Abuse and Mental Health Services Administration. Office of Applied Studies. 2003a. Emergency Department Trends from the Drug Abuse Warning Network; Final Estimates 1995-2002; DAWN Series D-24. Rockville, MD: US GPO.
73. US Department of Health and Human Services Substance Abuse and Mental Health Services Administration Office of Applied Studies (USDHHS) 2003b. Year 2002 National Survey on Drug Use and Health. Available at: www.samhsa.gov/oas/nhsda/2k2nsduh/Results/2k2Results.htm#l. I.
74. U S Drug Enforcement Administration (USDEA). 2004a. Annual Report: 2003 National Forensic Laboratory Information System. Arlington, VA: USDEA.
75. US Drug Enforcement Administration (USDEA). 2004b. Fentanyl (Trade names: Actiq. Duragesic) October 2004; DEA/ODE/03021. Arlington, VA: USDEA.
76. US Drug Enforcement Administration (USDEA). 2004c. DEA Briefs & Background, Drugs and Drug Abuse, Drug Descriptions, Pentazocine. Arlington, VA: USDEA.
77. US Drug Enforcement Administration (USDEA).2004d. Controlled Substance SchedulingActions 1985-1989. Arlington, VA: USDEA.
78. US Drug Enforcement Administration (USDEA). 2004e. National Forensic Laboratory Information System Annual Report for 2003. Arlington, VA: USDEA.
79. US Drug Enforcement Administration (USDEA). 2000a. Schedules of Controlled Substances: Exempt anabolic steroids products. Federal Register 65 (149):47306-309.
80. US Drug Enforcement Administration (USDEA). 2000b Anabolic steroids (correction). Federal Register 65 (13): 3124-26.
81. US Drug Enforcement Administration (USDEA). 1999. Final rule. Federal Register 64 (127): 35928-930.
82. US Drug Enforcement Administration (USDEA). 1998. Notice of proposed rulemaking. Federal Register 63: 59751-59753.
83. US Food and Drug Administration (USFDA). 2004. Guidance for Industry: Development and Use of Risk Minimization Action Plans (draft guidance). Washington DC: USGPO.
84. US Food and Drug Administration (USFDA). 1997a. Approval Letter: Application Number NDA 20-791, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/cder/foi/nda/97/7m91_TODEM%^2C1ITS%205MG%20PER%20DAY_APPROV.PDF
85. US Food and Drug Administration (USFDA). 1997b. Medical Review(s) Center for Drug Evaluation and Research; Application Number NDA 20-791. Available at: http://www.fda.gov/cder/foi/nda/97/20791_TESTODEM%2aiTS%205MG%20PER%20DAY_MEDR.PDF
86. US Food and Drug Administration (USFDA). 1997c. US Food and Drug Administration Modernization Act of 1997 (Section 111 of Title I, sect. 505a, “pediatric exclusivity”). 21 USC 355a. Available at: www.fda.gov/cder/guidance/2891 fnl.htm#l
87. US Pharmacopeia. 2004. US Pharmacopeia Fact Sheet. Rockville, MD: USP.
88. Volkow, N.D.; Fowler, J.S. & Wang, G. 2004. The addicted human brain viewed in the light of imaging studies: Brain circuits and treatment strategies. Neuropharmacology 47 (Suppl I): 3-13.
89. Volkow, N.D.; Fowler, J.S. & Wang, G. 1999. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. Journal of Psychopharmacology 13: 337-45.
90. Volkow, N.D.; Wang, G.; Fowler, J.S.; THanos, P.P.; Logan J.; Gatley, S.J.; Gifford, A.; Ding, Y.S.; Wong, C. & Pappas, N. 2002. Brain DA D2 receptors predict reinforcingeffects of stimulants in humans: Replication study. Synapse 46 (2): 79-82.
91. Volkow, N.D.; Wang, G.; Fowler, J.S; Hitzemann, R.; Angrist, B.; Gatley, S.J.; Logan, J.; Ding, Y.S. & Pappas, N. 1999a. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: Implications in addiction. American Journal of Psychiatry 156: 19-26.
92. Volkow, N.D.; Wang G.; Fowler, J.S.; Gatley S.J.; Logan, J.; Ding, Y.S.; Dewey, S.L.; Hitzemann, R.; Gifford, AN. & Pappas, N. 1999b. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of “high". Journal of Pharmacology and Experimental Therapeutics 288:1420.
93. Volkow N.D.; Wang, G.; Fischman, M.W.; Foltin R.W.; Fowler J.S.; Abumrad, N.N.; Vitkun, S.; Logan, J.; Gatley, S.J.; Pappas N.; Hitzemann, R. & Shea, K. 1997. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386 (6627): 827-30.
94. Volkow, N.D.; Ding, Y-S.; Fowler, J.S. & Wang, G. 1996. Cocaine addiction: Hypothesis derived from imaging studies with PET. Journal of Addictive Diseases 15: 55-71.
95. Volkow, N.D.; Ding, Y.-S.; Fowler, J.S.; Wang, G.-J.; Logan, J.; Gatley, J.S.; Dewey, S.;Ashby, C.; Liebermann, J.; Hitzemann R. & Wolf, A. 1995. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry 52 (6): 456-63.
96. Weil, A. & Rosen, W. 1993. From Chocolate to Morphine: Everything You Need to Know About Mind-Altering Drugs. Boston: Houghton Mifflin Company.
97. Wesson, D.R. 2004. Buprenorphine in the treatment of opiate dependence: Its pharmacology and social context of use in the U.S. Journal of Psychoactive Drugs May (Suppl 2): 119-28.
98. Wolters Kluwer Health Inc. 2004. Drug Facts and Comparisons. 58th Ed. St. Louis, MO: Wolters Kluwer Health.
99. Work, H. MD. George Latrop Bradley and the War OverRitalin. Available at: www.cosmos-club.org/journals/2001/work.html.
100. Wu Chen, N.B. 1999. Fentanyl intoxication: Suicide by transdermal patch. Paper presented to American Academy of Forensic Sciences. Colorado Springs, CO.